Hepatitis C virus treatment: The unyielding chasm between efficacy and effectiveness

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 8, 2014, Pages 1381-1383

  Kanwal, Fasiha ^a,b,c   El Serag, Hashem B ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; TELAPREVIR; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PROLINE;

ANTIVIRAL THERAPY; DRUG EFFICACY; DRUG TREATMENT FAILURE; EDITORIAL; HEPATITIS C; HUMAN; LABORATORY TEST; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; PATIENT COMPLIANCE; RISK ASSESSMENT; SHORT COURSE THERAPY; VIRUS LOAD; ANEMIA; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DECOMPENSATED LIVER CIRRHOSIS; DEMOGRAPHY; GENOTYPE; HEALTH CARE POLICY; HEALTH INSURANCE; HEPATITIS C VIRUS; LIVER DISEASE; MATHEMATICAL MODEL; MEDICAL INFORMATION; MORBIDITY; MORTALITY; QUALITY OF LIFE; STANDARD; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; FEMALE; HEPATITIS C, CHRONIC; MALE;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; OLIGOPEPTIDES; PROLINE;

EID: 84904389132     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.02.031     Document Type: Editorial

References (21)

1. Armstrong G.L., Wasley A., Simard E.P., et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714.
2. Morgan R.L., Baack B., Smith B.D., et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013, 158(Pt 1):329-337.
3. Backus L.I., Boothroyd D.B., Phillips B.R., et al. Asustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011, 9:509-516.
4. Spiegel B.M., Younossi Z.M., Hays R.D., et al. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005, 41:790-800.
5. Lawitz E., Mangia A., Wyles D., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. NEngl J Med 2013, 368:1878-1887.
6. Zeuzem S., Berg T., Gane E., et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014, 146:430-441.
7. Fried M.W., Buti M., Dore G.J., et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013, 58:1918-1929.
8. Jacobson I.M., Ghalib R.H., Rodriguez-Torres M., et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study. Hepatology 2013, 58:1379A.
9. Jesudian A.B., de Jong Y.P., Jacobson I.M. Emerging therapeutic targets for hepatitis C virus infection. Clin Gastroenterol Hepatol 2013, 11:612-619.
10. Ioannou G.N., Beste L.A., Green P.K. Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans. Clin Gastroenterol Hepatol 2014, 12:1371-1380.
11. Backus L.I., Gavrilov S., Loomis T.P., et al. Clinical Case Registries: simultaneous local and national disease registries for population quality management. JAm Med Inform Assoc 2009, 16:775-783.
12. Kramer J.R., Kanwal F., Richardson P., et al. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. JHepatol 2012, 56:320-325.
13. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. NEngl J Med 2011, 364:1195-1206.
14. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416. ADVANCE Study Team.
15. Volk M.L., Tocco R., Saini S., et al. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009, 50:1750-1755.
16. Lettmeier B., Muhlberger N., Schwarzer R., et al. Market uptake of new antiviral drugs for the treatment of hepatitis C. JHepatol 2008, 49:528-536.
17. Davis G.L., Alter M.J., El-Serag H., et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010, 138:513-521.
18. Stepanova M., Kanwal F., El-Serag H.B., et al. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology 2011, 53:737-745.
19. Backus L.I., Belperio P.S., Loomis T.P., et al. Hepatitis C virus screening and prevalence among US veterans in Department of Veterans Affairs care. JAMA Intern Med 2013, 173:1549-1552.
20. Moyer V.A. US Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013, 159:349-357.
21. Kanwal F., Lok A.S., El-Serag H.B. CDC and USPSTF 2012 recommendations for screening for hepatitis C virus infection: overview and take-home messages. Clin Gastroenterol Hepatol 2013, 11:200-203.